Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Busse

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|May 29, 2007
The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled studySally Wenzel, William Busse, William Calhoun, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 28, 2019
Global Initiative for Asthma 2016-derived asthma control with fluticasone propionate and salmeterol: A Gaining Optimal Asthma Control (GOAL) study reanalysisEric D Bateman, William Busse, Søren E Pedersen, et al.
The Journal of Allergy and Clinical Immunology|January 18, 2003
Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice dailyWilliam Busse, Steven M Koenig, John Oppenheimer, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 26, 2018
Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World StudyThomas B Casale, Allan T Luskin, William Busse, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 9, 2006
Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukastDavid S Pearlman, Janet van Adelsberg, George Philip, et al.
BMC Pulmonary Medicine|April 30, 2017
Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL studyJean Bousquet, Neil Barnes, Michael Gibbs, et al.
American Journal of Respiratory and Critical Care Medicine|September 18, 2007
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthmaPatrick Flood-Page, Cheri Swenson, Isidore Faiferman, et al.
BMC Pulmonary Medicine|November 15, 2022
Patients with allergic asthma have lower risk of severe COVID-19 outcomes than patients with nonallergic asthmaThomas R Murphy, William Busse, Cecile T J Holweg, et al.
American Journal of Respiratory and Critical Care Medicine|March 9, 2013
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA studyNicola A Hanania, Sally Wenzel, Karin Rosén, et al.
American Journal of Respiratory and Critical Care Medicine|January 9, 2010
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthmaJonathan Corren, William Busse, Eli O Meltzer, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|May 29, 2007
The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled studySally Wenzel, William Busse, William Calhoun, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 28, 2019
Global Initiative for Asthma 2016-derived asthma control with fluticasone propionate and salmeterol: A Gaining Optimal Asthma Control (GOAL) study reanalysisEric D Bateman, William Busse, Søren E Pedersen, et al.
The Journal of Allergy and Clinical Immunology|January 18, 2003
Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice dailyWilliam Busse, Steven M Koenig, John Oppenheimer, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 26, 2018
Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World StudyThomas B Casale, Allan T Luskin, William Busse, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 9, 2006
Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukastDavid S Pearlman, Janet van Adelsberg, George Philip, et al.
BMC Pulmonary Medicine|April 30, 2017
Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL studyJean Bousquet, Neil Barnes, Michael Gibbs, et al.
American Journal of Respiratory and Critical Care Medicine|September 18, 2007
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthmaPatrick Flood-Page, Cheri Swenson, Isidore Faiferman, et al.
BMC Pulmonary Medicine|November 15, 2022
Patients with allergic asthma have lower risk of severe COVID-19 outcomes than patients with nonallergic asthmaThomas R Murphy, William Busse, Cecile T J Holweg, et al.
American Journal of Respiratory and Critical Care Medicine|March 9, 2013
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA studyNicola A Hanania, Sally Wenzel, Karin Rosén, et al.
American Journal of Respiratory and Critical Care Medicine|January 9, 2010
A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthmaJonathan Corren, William Busse, Eli O Meltzer, et al.
Pageof 5